Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.10.23	Biotech Stocks Facing FDA Decision In November 2023 (RTTNews)
26.10.23	Merck Reports Higher Profit For Q3; Revises Full-year Outlook (RTTNews)
25.10.23	Merck: KEYTRUDA Plus LENVIMA Is Available In Canada To Treat Advanced Or Metastatic Kidney Cancer (RTTNews)
23.10.23	Immutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLC (RTTNews)
20.10.23	Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers (RTTNews)
20.10.23	Daiichi Sankyo, Merck Reach $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates (RTTNews)
20.10.23	Daiichi Sankyo, Merck Reach Up To $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates (RTTNews)
16.10.23	EC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung Cancer (RTTNews)
10.10.23	Merck: KEYNOTE-671 Trial Meets Dual Primary Endpoint - Quick Facts (RTTNews)
05.10.23	Merck: KEYTRUDA Positive Trial Results In Certain Patients With Muscle-Invasive Urothelial Carcinoma (RTTNews)
28.09.23	Merck Gets Priority Review For Biologics License Application For Sotatercept (RTTNews)
22.09.23	Merck: LEAP-006, LEAP-008 Trials Fails To Meet Dual Primary Endpoints (RTTNews)
22.09.23	Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints (RTTNews)
20.09.23	Merck Says FDA Grants Priority Review For KEYTRUDA+Concurrent Chemoradiotherapy For Cervical Cancer (RTTNews)
19.09.23	Merck: FDA Grants Priority Review For SNDA Seeking Approval For WELIREG (RTTNews)
15.09.23	Merck Gets Positive CHMP Opinion For Approval Of KEYTRUDA To Treat Non-Small Cell Lung Cancer (RTTNews)
10.09.23	Gilead : Phase 2 Study Of Trodelvy Combination Shows Promising Clinical Activity In Lung Cancer (RTTNews)
05.09.23	Merck Animal Health Recalls Banamine/Banamine-S Injection (RTTNews)
18.08.23	Merck Announces First Positive Phase 3 Results For WELIREG From LITESPARK-005 (RTTNews)
07.08.23	Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial (PR Newswire)
01.08.23	Merck & Co Inc. Q2 Earnings Summary (RTTNews)
28.07.23	Merck: Phase 3 KEYNOTE-756 Trial Meets Primary Endpoint In Early-Stage ER+/HER2- Breast Cancer (RTTNews)
27.07.23	Merck Says 21-valent Pneumococcal Conjugate Vaccine,V116, Meets Key Endpoints In Phase 3 Trials (RTTNews)
25.07.23	Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement (PR Newswire)
21.07.23	Merck's Gefapixant Drug For Chronic Cough A Step Away From Approval In Europe (RTTNews)
19.07.23	Merck: Phase 3 KEYTRUDA Trial Meets Primary Endpoint Of PFS In Advanced Cervical Cancer (RTTNews)
27.04.23	Merck Q1 Results Top Estimates; Boosts FY23 Outlook (RTTNews)
16.04.23	Prometheus Biosciences To Be Acquired By Merck (RTTNews)
13.04.23	Merck's KEYTRUDA One Step Closer To Gastric Cancer Treatment Expansion (RTTNews)
12.04.23	Merck: FDA Places Partial Clinical Hold On Initiation Of New Patients On Evobrutinib (RTTNews)
07.04.23	Merck, Eisai Announce Disappointing Results From Phase 3 LEAP-003 And LEAP-017 Trials (RTTNews)
10.03.23	Merck: Phase 2/3 CCTG IND.227/KEYNOTE-483 Trial With KEYTRUDA Meets Primary Endpoint (RTTNews)
01.03.23	Merck: Phase 3 KEYNOTE-671 Trial With KEYTRUDA Meets One Of Its Dual Primary Endpoints (RTTNews)
24.02.23	Merck: CHMP Recommends Against Approval Of Lagevrio For Treatment Of Certain Adults With COVID-19 (RTTNews)
03.02.23	Personalis, Moderna Continue Partnership On Personalized Cancer Vaccine Program (RTTNews)
03.02.23	Merck's KEYTRUDA Plus Chemotherapy Meets Primary Goal As First-Line Therapy In Endometrial Carcinoma (RTTNews)
02.02.23	Merck Q4 Profit Down, Adj. EPS Tops View; Sees Weak FY23 Adj. EPS, Below Market (RTTNews)
27.01.23	Merck's KEYTRUDA Gets FDA Approval To Treat Stage IB, II, IIIA Non-small Cell Lung Cancer Patients (RTTNews)
26.01.23	Merck Animal Health: FDA Approves Expanded Indication For BRAVECTO Chews For Dogs (RTTNews)
20.01.23	Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment (RTTNews)
18.01.23	Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort (PR Newswire)
11.01.23	Merck To Complete Acquisition Of Imago (RTTNews)
30.12.22	China Approves Merck's Covid-19 Drug For Emergency Use (RTTNews)
27.12.22	Biotech Stocks Facing FDA Decision In January 2023 (RTTNews)
22.12.22	Merck, Kelun-Biotech Collaborate To Develop Seven Preclinical ADC For Treatment Of Cancer (RTTNews)
20.12.22	Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
15.12.22	AstraZeneca: FDA To Extend PDUFA Date Regarding SNDA For Lynparza With Abiraterone (RTTNews)
13.12.22	Moderna, Merck's Phase 2b Trial Of MRNA-4157/V940 Combination In Melanoma Meets Primary Endpoint (RTTNews)
12.12.22	Merck Commences Tender Offer To Acquire Imago BioSciences (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’315.50	3.50 %	K V
UBS Group	28.75	2.46 %	K V
CieFinRichemont	166.75	2.18 %	K V
Holcim	99.70	2.05 %	K V
Sika	233.60	1.88 %	K V
Swisscom	529.50	-0.38 %	K V
Novartis	96.35	-0.60 %	K V
Sonova Hldg	267.30	-1.55 %	K V
Swiss Life Hldg	770.40	-2.13 %	K V
Givaudan	3’967.00	-2.15 %	K V

mehr

14.03.25		S&P 500-Handel aktuell: S&P 500 schlussendlich auf grünem Terrain
14.03.25		Optimismus in New York: NASDAQ 100 zum Handelsende mit Gewinnen
14.03.25		NYSE-Handel: So bewegt sich der Dow Jones aktuell
14.03.25		Aufschläge in New York: NASDAQ 100 nachmittags in Grün
14.03.25		Freitagshandel in New York: S&P 500 nachmittags stärker
14.03.25		Aufschläge in New York: So bewegt sich der NASDAQ 100 am Freitagmittag
14.03.25		Aufschläge in New York: S&P 500 mit grünem Vorzeichen
14.03.25		Gewinne in Europa: Schlussendlich Gewinne im STOXX 50

14.03.25

S&P 500-Handel aktuell: S&P 500 schlussendlich auf grünem Terrain

14.03.25

Optimismus in New York: NASDAQ 100 zum Handelsende mit Gewinnen

14.03.25

NYSE-Handel: So bewegt sich der Dow Jones aktuell

14.03.25

Aufschläge in New York: NASDAQ 100 nachmittags in Grün

14.03.25

Freitagshandel in New York: S&P 500 nachmittags stärker

14.03.25

Aufschläge in New York: So bewegt sich der NASDAQ 100 am Freitagmittag